Atossa Therapeutics (NASDAQ:ATOS) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer ...
SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
The average one-year price target for Atossa Therapeutics (NasdaqCM:ATOS) has been revised to $44.62 / share. This is a decrease of 31.37% from the prior estimate of $65.02 dated March 25, 2026. The ...
The MarketWatch News Department was not involved in the creation of this content. Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, ...
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let ...
What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...
Atossa Therapeutics (ATOS 1.23%) has been a top-performing biotech stock rising more than this year. Successful results from a mid-stage clinical trial with a potential new breast cancer treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results